Safety of Intravitreal Dexamethasone Implant (Ozurdex)

Malclès, Ariane; Dot, Corinne; Voirin, Nicolas; Vié, Anne-Laure; Agard, Émilie; Bellocq, David; Denis, Philippe; Kodjikian, Laurent

doi:10.1097/iae.0000000000001369

Cited by 129 publications

(83 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, percentage of patients who required IOP-lowering medication following the injection has been reported between 10.9% and 54%. IOP elevation is usually well-controlled with IOP-lowering medication in most of studies and the rate of patients who underwent glaucoma surgery is not reported more than 2% in any study [28][29][30][31][32][33][34][35][36][37][38][39][40][41][42] .…”

Section: Major Clinical Trials Evaluating I O P C H a N G E S A F T Ementioning

confidence: 84%

“…IOP elevation is considered a common adverse event that may occur after the administration. IOP outcomes in clinical trials of IDI are summarized in Table 1 [28][29][30][31][32][33][34][35][36][37][38][39][40][41][42] . Different studies have reported the rates of IOP of > 25 mmHg in patients who developed IOP elevation following IDI administration are ranged from 7.1% to 58.7%.…”

Section: Major Clinical Trials Evaluating I O P C H a N G E S A F T Ementioning

confidence: 99%

See 1 more Smart Citation

Intraocular Pressure Changes Following the Administration of Intravitreal Dexamethasone Implant: A Mini -Review

Kartı

Saatçi²

2019

International Journal of Ophthalmic Research

View full text Add to dashboard Cite

show abstract

Section: Major Clinical Trials Evaluating I O P C H a N G E S A F T Ementioning

confidence: 84%

Section: Major Clinical Trials Evaluating I O P C H a N G E S A F T Ementioning

confidence: 99%

Intraocular Pressure Changes Following the Administration of Intravitreal Dexamethasone Implant: A Mini -Review

Kartı

Saatçi²

2019

International Journal of Ophthalmic Research

View full text Add to dashboard Cite

show abstract

“…Most importantly, 97% of the cases were controlled using topical medication alone. 3% required oral medication and only 0.7% required filtration surgery [13]. Another study reported IOP elevation > 10 mmHg from baseline or > 25 mmHg in 8.6% of patients at month 1 and 25% at month 4 [14].…”

Section: Discussionmentioning

confidence: 98%

Intraocular Pressure Control for Patients Undergoing Combination Intravitreal Anti-VEGF and Dexamethasone Therapy for Macular Edema from Retinal Vein Occlusion

Singer¹,

Bell²,

Singer³

et al. 2018

JPT

View full text Add to dashboard Cite

Background and Objective: Sustained-release dexamethasone intravitreal implant is an effective treatment for macular edema secondary to retinal vein occlusion (RVO) but ocular hypertension is a side effect. This study evaluated whether the addition of a single combination IOP-lowering medication will reliably control intraocular pressure (IOP) for those patients. Study Design/Patients and Methods: Retrospective chart review of 62 patients that underwent multiple injections of combination anti-VEGF and sustained-release dexamethasone intravitreal implant for macular edema secondary to RVO. IOP spikes were treated with brimonidine 0.2% - timolol 0.5%. IRB approval was obtained. Results: The average elevated IOP requiring treatment was 28.6 mmHg. The average IOP after adding brimonidine 0.2% - timolol 0.5% was 16.7 mmHg. 100 percent of treatment cycles had an IOP< 30 mmHg after starting treatment. Conclusions: Using one combination IOP-lowering drop can reliably control the ocular hypertension that occurs secondary to combination therapy for macular edema in RVO.

show abstract

“…Не наблюдалось гифемы и кровоизлияний в стекловидное тело, что позволяет судить об оптимальной фиксации диафрагмы и отсутствии повреждения цилиарного тела и передних цилиарных сосудов [9]. Увеличение внутриглазного давления наблюдалось через 1 месяц после интравитреального введения импланта дексаметазона, что, по данным исследований, может встречаться в среднем у 28,5 % пациентов, в лечении которых был использован Ozurdex [16]. Нормализация внутриглазного давления была достигнута путем топического применения антиглаукомного препарата.…”

Section: результаты и обсуждениеunclassified

Clinical and Functional Outcomes of Lens-Iris Diaphragm Implantation with Simultaneous Subtotal Penetrating Keratoplasty: a 15-Year Follow-Up Case Report

et al. 2019

View full text Add to dashboard Cite

Combined traumatic injuries of the anterior eye segment are attributed to the severe consequences of the injured organ of vision. Iris defects result in spherical and chromatic aberrations, diplopia, flares, severe photophobia, cosmetic defects, and significantly reduced visual acuity after the injury. The literature describes various methods to restore visual functions impaired as a result of aniridia. Use of an artificial iris together with an intraocular lens pathology results in optimal reconstruction and recovery of normal anterior segment anatomy and topography. In this paper, we provide a report on a patient followed up for 15 years after combined reconstruction eye surgery for an off-the-job penetrating eye injury sustained in 2003. A complex intervention was required due to the involvement of the cornea, iris, and lens. In 2004, the patient underwent a lens-iris diaphragm implantation combined with penetrating keratoplasty. The diaphragm implantation was followed by an improvement in visual acuity and elimination of photophobia and flares. There were no intra- or postoperative complications. Two years later, LASIK refractive surgery was performed on the corneal transplant to eliminate induced ametropia. The patient retained good eye function, with a stable position of the lens-iris diaphragm, for many years after the diaphragm implantation, keratoplasty, and refractive surgery. In 2018, he had an intravitreal implant impregnated with dexamethasone, as changes in the retina had developed. The long-term follow-up in this case demonstrates that the implantation of a lens-iris diaphragm resulted in an elimination of undesirable optical events associated with aniridia and produced an optimal functional result, while also improving the patient’s quality of life with a good aesthetic effect.

show abstract

Safety of Intravitreal Dexamethasone Implant (Ozurdex)

Abstract: Episodes of ocular hypertension after Ozurdex implant were generally transient and successfully managed with topical treatment. An analysis of the risk factors may help to determine the risk-benefit ratio for individual patients treated with dexamethasone implants.

Cited by 129 publications

References 25 publications

Intraocular Pressure Changes Following the Administration of Intravitreal Dexamethasone Implant: A Mini -Review

Intraocular Pressure Changes Following the Administration of Intravitreal Dexamethasone Implant: A Mini -Review

Intraocular Pressure Control for Patients Undergoing Combination Intravitreal Anti-VEGF and Dexamethasone Therapy for Macular Edema from Retinal Vein Occlusion

Clinical and Functional Outcomes of Lens-Iris Diaphragm Implantation with Simultaneous Subtotal Penetrating Keratoplasty: a 15-Year Follow-Up Case Report

Contact Info

Product

Resources

About